[1]
J. Demeter, J. Weisinger, and Z. Nagy, “Mild clinical course of COVID-19 infection in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitors (TKIs) without interruption”, Mediterr J Hematol Infect Dis, vol. 13, no. 1, p. e2021022, Feb. 2021.